Latest Breaking News On - Venture investment - Page 14 : comparemela.com

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

West midlandsUnited kingdom generalUnited kingdomJon townendNewton biocapitalAdeline meilhocStefan klotterTim mayoMark thomasUniversity hospitals birminghamCardiovascular research unit at northernConsultant cardiologist at university hospitals birminghamInstitute of cardiovascular sciencesEuropean medicines agencyFrench national institute of healthVenture investment

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomWest midlandsUnited kingdom generalMark thomasJon townendTim mayoNewton biocapitalAdeline meilhocUniversity of birminghamCardiovascular research unit at northernUniversity hospitals birminghamBirmingham health partnersVenture investmentInstitute of cardiovascular sciencesEuropean medicines agencyMidlands academic health science network

The University of Birmingham and Acticor Biotech announce

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce.

West midlandsUnited kingdom generalUnited kingdomTim mayoAdeline meilhocMark thomasNewton biocapitalJon townendMidlands academic health science networkUniversity of birminghamBirmingham health partnersVenture investmentUniversity of sheffieldEuropean medicines agencyFrench national institute of healthInstitute of cardiovascular sciences

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomStefan klotterNewton biocapitalRegulation of the french financial markets authorityFrench national institute of healthEuropean medicines agencyVenture investmentRegulatory newsFrench commercial codeGeneral regulationFrench financial markets authorityEuronext growth parisFrench national instituteMedical researchLancet neurologyActicor biotech

Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024

25.01.2024 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its financial agenda for the 1st half of .

United kingdomNewton biocapitalVenture investmentEuropean medicines agencyFrench national institute of healthFrench national instituteMedical researchActicor biotechEuronext growth parisActicor biotech stockEuronext parisActicor biotech chartCticor biotech kursCticor biotech aktie